Since 2018, Xellera Therapeutics has operated Hong Kong’s first commercial cGMP facility for cell and gene therapies. We offer fully integrated CDMO services—including process development, GMP manufacturing, analytical testing, and cryostorage—adhering to US FDA, EMA, and PIC/S guidelines to accelerate ATMP progress across Asia. https://www.xelleratherapeutics.com/